C DIFF FOUNDATION nag-retweet

Last week, we announced the publication of Phase 3 ECOSPOR III study data in the New England Journal of Medicine highlighting SER-109, an investigational oral #microbiome therapeutic for recurrent #Cdiff infection. Learn more: bit.ly/3KteyDA #ICYMI

English

















